Efinaconazole in the treatment of onychomycosis

Efinaconazole in the treatment of onychomycosis

Shari R Lipner, Richard K Scher Department of Dermatology, Weill Cornell Medical College, New York, NY, USA Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol...

Full description

Bibliographic Details
Main Authors: Lipner SR, Scher RK
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:Infection and Drug Resistance
Online Access:http://www.dovepress.com/efinaconazole-in-the-treatment-of-onychomycosis-peer-reviewed-article-IDR
Description
Summary:Shari R Lipner, Richard K Scher Department of Dermatology, Weill Cornell Medical College, New York, NY, USA Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. Keywords: efinaconazole, Jublia, onychomycosis, fungal infection, nail infection 
ISSN:1178-6973

Similar Items